SCHEMBL8064837

SCHEMBL8064837

Oc1cccc(Nc2ccc(Oc3cccc(N4CCOCC4)c3)cn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.51
PKMYT1 Q99640 2/20 0.50
KMT2A Q03164 1/20 0.49
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
PIK3CA P42336 5/20 0.46
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
CDK2 P24941 2/20 0.44
CCNT1 O60563 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK9 P50750 1/20 0.44
TTBK1 Q5TCY1 1/20 0.44
TTBK2 Q6IQ55 1/20 0.44
APP P05067 1/20 0.43
TGFBR1 P36897 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651256 0.88 MET (0.51) METKMT2APIK3CACDK2CDK9
SCHEMBL3655868 0.85 DGAT1 (0.51) METKMT2AGABRG2GABRB3GABRA5
SCHEMBL3655673 0.84 MET (0.54) METHDAC3HDAC1HDAC2HDAC6
SCHEMBL3655694 0.84 MET (0.63) METHDAC3HDAC1HDAC2HDAC6
SCHEMBL8068266 0.81 MET (0.49) METCDK2CCNT1CCNE1CDK9
SCHEMBL3594431 0.77 APP (0.61) PKMYT1KMT2AHDAC3HDAC1HDAC2
SCHEMBL3704093 0.76 APP (0.51) KMT2AHDAC6PIK3CAAPPRAB9A
SCHEMBL2599593 0.75 AKR1C3 (0.45) KMT2A
SCHEMBL3656146 0.75 HDAC6 (0.51) KMT2AHDAC6APP
SCHEMBL3653866 0.75 APP (0.75) KMT2AHDAC6APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
WO-2009044160-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HCRTR1, HCRTR2, RTN3 MET 463/4885PKMYT1 3861/4885KMT2A 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.